Mar 21 |
Why Celcuity (CELC) Might Surprise This Earnings Season
|
Mar 20 |
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
|
Mar 6 |
Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024
|
Feb 28 |
Celcuity to Participate in Cowen’s 44th Annual Health Care Conference
|
Feb 22 |
Stifel starts Celcuity at buy, sees gedatolisib as potential blockbuster
|
Feb 22 |
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer
|
Feb 20 |
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
|
Jan 22 |
Celcuity Inc. (NASDAQ:CELC) has caught the attention of institutional investors who hold a sizeable 33% stake
|
Dec 6 |
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium
|
Dec 1 |
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium
|